CMI Pertussis Boost Class 18: Mini Project

Barry Grant UC San Diego

http://thegrantlab.org

Exploring Pertussis Vaccination Through Systems Vaccinology


Pertussis is a leading causes of vaccine-preventable deaths

Pertussis, or **whooping cough**, is a highly contagious lung infection caused by the bacteria *Bordetella pertussis*.

- Over 16 million cases & 200,000 associated infant deaths annually. (Blake et al. 2016)
- Can infect people of all ages but is most severe and life threatening for infants under a year old. (Video link)
- Transmission occurs primarily through bacteria laden respiratory droplets produced when an infected individual coughs and sneezes.

Bordetella pertussis attacks cells lining the airways


The bacteria use adhesive proteins to stick to ciliated cells whilst releasing toxins





Bordetella pertussis attacks cells lining the airways


The bacteria use adhesive proteins to stick to ciliated cells whilst releasing toxins





Pertussis is primarily a toxin-mediated disease


These toxins damage cilia, suppress the immune response and disrupt signaling leading to inflammation, mucus buildup and impaired function






Pertussis develops in three main phases

Time (weeks)											"100-day	cough"
1	2	3	4	5	6	7	8	9	10	11	12	13
Initial Infection	Catarrha Early Syn (1-2 week • Runny n • Cough • Mild feve • Highly contagio	nptoms ks) iose er	Severe S (1-6 week • Paroxys • Inhalato • Difficulty • Vomiting	Severe SymptomsRecovery(1-6 weeks but may last up to 10 weeks)(2-3 weeks)• Paroxysms (uncontrollable coughing fits)• Gradual• Inhalatory "whooping" sounds• Reduce• Difficulty breathing• Susception				Reduce	(lessening d coughir tible to ot	g of sympt		



Fascinating history

1578



CMI-PB

www.cmi-pb.org

The Name "Pertussis" First Appears


The name pertussis (from Latin for "intensive cough") was first introduced by the English physician Thomas Sydenham in 1670. This name took over by the end of the decade. Earlier names included hooping cough, tusis perennis, tussis epidemica infantum, and tusis quinta.

Read more



The oldest known pertussis epidemic is thought to be the Paris outbreak of 1578. This was documented in detail by the French physician Guillaume de Baillou who described the classic symptoms of the disease.

Read more




Interactive Timeline >





First DPT Vaccine

Pearl Kendrick at the Michigan Department of Health combined a refined whole-cell pertussis vaccine with Diphtheria and Tetanus toxoids to create the first combination DPT vaccine.



Decline of Whooping Cough

There was a massive dealing of nortwools assess in the LLC and other



First Whole-cell Pertussis Vaccine Tested on a Wide Scale

Danish physician Thorvald Madsen tested a whole-cell pertussis vaccine on a wide scale for the first time reporting promising results.



Routine Vaccination

In 1944, the Committee on Infectious Diseases of the American Academy of Pediatrics suggests routine use of pertussis vaccine and, in 1947, recommends its use in the form of the DPT combination. Routine childhood vaccination begins and is made made compulsory in some states by the end of the decade.



Interactive Timeline >



First Whole-cell Pertussis Vaccine Tested on a Wide Scale

Danish physician Thorvald Madsen tested a whole-cell pertussis vaccine on a wide scale for the first time reporting promising results.




Routine Vaccination

In 1944, the Committee on Infectious Diseases of the American Academy of Pediatrics suggests routine use of pertussis vaccine and, in 1947, recommends its use in the form of the DPT combination. Routine childhood vaccination begins and is made made compulsory in some states by the end of the decade.




Interactive Timeline >




First DPT Vaccine

Pearl Kendrick at the Michigan Department of Health combined a refined whole-cell pertussis vaccine with Diphtheria and Tetanus toxoids to create the first combination DPT vaccine.



Decline of Whooping Cough

There uses a measure dealing of nexturnin access in the LLC and other



Creation of DTaP Vaccine

Japanese scientist Yugi Sato created an acellular pertussis vaccine that contained purified haemagglutinins from *B. Pertussis*. This **aP vaccine** was first used in Japan soon after and was demonstrated to have fewer side effects than the whole-cell (**wP**) vaccine. It was later used in other countries (with additional components of *B. Pertussis*) as the combined DTaP vaccine.

Read more



Liability

By 1984 DPT vaccine manufacturers had a hard time obtaining liability insurance. By the end of the year, only one DPT manufacturer remained. Scientists respond by ramping up development and testing of safer new acellular pertussis vaccines. These would replace the older whole cell vaccine in many countries with a decade.






"DPT: Vaccine Roulette"

In 1982 negative publicity was encouraged from a documentary called "DPT: Vaccine Roulette", which led to a massive amount of lawsuits against the vaccine manufacturers. This documentary depicted the lives of children whose severe disabilities were incorrectly blamed on the DPT vaccine.

Read more





Creation of DTaP Vaccine

Japanese scientist Yugi Sato created an acellular pertussis vaccine that contained purified haemagglutinins from *B. Pertussis*. This **aP vaccine** was first used in Japan soon after and was demonstrated to have fewer side effects than the whole-cell (**wP**) vaccine. It was later used in other countries (with additional components of *B. Pertussis*) as the combined DTaP vaccine.

Read more



Liability

By 1984 DPT vaccine manufacturers had a hard time obtaining liability insurance. By the end of the year, only one DPT manufacturer remained. Scientists respond by ramping up development and testing of safer new acellular pertussis vaccines. These would replace the older whole cell vaccine in many countries with a decade.






"DPT: Vaccine Roulette"

In 1982 negative publicity was encouraged from a documentary called "DPT: Vaccine Roulette", which led to a massive amount of lawsuits against the vaccine manufacturers. This documentary depicted the lives of children whose severe disabilities were incorrectly blamed on the DPT vaccine.

Read more





Later studies showed that their was no connection between the DPT vaccine and the permanent brain damage. It was in fact called a "Myth" and "Nonsence" by the Journal of American Medical Association in 1990.



The acellular pertussis (aP) vaccine was approved in the U.S in 1992, the the older wP formalization was phased out and completely replaced with the DTaP vaccine combination in 1996.




CMI-PB Project

A new <u>systems vaccinology project</u> is launced that combines systems biology and genomics to provide a more holistic picture of protective pertussis-specific immune mechanisms. The project provides the scientific community with comprehensive, high-quality, and freely accessible resources related to Pertussis booster vaccination.

These resources, and associated <u>prediction challenges</u>, are geared towards engaging both experts and enthusiasts in developing and improving **computational models** of the immune response to vaccination and in turn informing new intervention strategies to curb the increasing frequency of *B. pertussis* infection.





Pertussis Outbreaks

Major pertussis epidemics and outbreaks are once again a major public health concern. With epidemics typically occurring every 3 to 5 years in the U.S. as was evident in the pre-vaccine years. TO FINISH mention CA outbreak.



Later studies showed that their was no connection between the DPT vaccine and the permanent brain damage. It was in fact called a "Myth" and "Nonsence" by the Journal of American Medical Association in 1990.

aP Vaccine Approved in the U.S.

The acellular pertussis (aP) vaccine was approved in the U.S in 1992, the the older wP formalization was phased out and completely replaced with the DTaP vaccine combination in 1996.




CMI-PB Project

A new <u>systems vaccinology project</u> is launced that combines systems biology and genomics to provide a more holistic picture of protective pertussis-specific immune mechanisms. The project provides the scientific community with comprehensive, high-quality, and freely accessible resources related to Pertussis booster vaccination.

These resources, and associated <u>prediction challenges</u>, are geared towards engaging both experts and enthusiasts in developing and improving **computational models** of the immune response to vaccination and in turn informing new intervention strategies to curb the increasing frequency of *B. pertussis* infection.

Timeline >



Pertussis Outbreaks

Major pertussis epidemics and outbreaks are once again a major public health concern. With epidemics typically occurring every 3 to 5 years in the U.S. as was evident in the pre-vaccine years. TO FINISH mention CA outbreak.

Hands-On Student Worksheet


● ● ● ■ ∨ < > ■ bioboot.github.io/cmi-pb_teaching/introduction/intro_to_cmi-pb.html ♂	0 Ê + C
IIII G Home 🎀 Gmail G Gcal 💭 GitHub 🌐 BIMM143 🌐 BGGN213 🌐 BGGN239 🛆 GDrive 🤧 Atmosphere 🝷 CloudLaunch 🌐 BIMM194 [B Teaching Material - Pertussis and the CMI-PB project	Blink 🗎 News 🗸 🗎 + 🗸
1. Investigating pertussis cases by year	Sections
	Background
The United States <i>Centers for Disease Control and Prevention</i> (CDC) has been compiling reported pertussis case numbers since 1922 in their <i>National Notifiable Diseases Surveillance System</i> (NNDSS). We can view this data on the	 Investigating pertussis cases by year
CDC website here: https://www.cdc.gov/pertussis/surv-reporting/cases-by-year.html	2. A tale of two vaccines (wP & aP)
• Q1. With the help of the R "addin" package <u>datapasta</u> assign the CDC pertussis case number	3. Exploring CMI-PB data
data to a data frame called cdc and use ggplot to make a plot of cases numbers over time.	4. Examine IgG Ab titer levels
	5. Obtaining CMI-PB RNASeq data
♀ Hint >	6. Working with larger datasets [OPTIONAL]
	O Edit this page
Key point. Partussis vaccination is in general, highly effective at preventing the disease. In the pre-vaccine	Report an issue


Key point: Pertussis vaccination is, in general, highly effective at preventing the disease. In the pre-vaccine era (before 1946) pertussis was a much more common disease and a major cause of infant mortality <u>2</u>. As we see clearly from analysis of the CDC tracking data above, introduction of the first pertussis vaccination in the United States in 1946 resulted in a dramatic reduction in the number of yearly cases from > 200,000 in the 1940s to < 2,000 in the 1970s.

2. A tale of two vaccines (wP & aP)

Two types of pertussis vaccines have been developed: whole-cell pertussis (wP) and acellular pertussis (aP). The

https://tinyurl.com/pertussiscdc





Side-Note: Using ggplot with custom y-axis scale

```
library(ggplot2)
base <- ggplot(cdc) +</pre>
  aes(Year, Cases) +
  geom_point() +
  geom_line() +
  labs(title="Pertussis Cases by Year (1922-2019)", y="Number of cases") +
  scale_y_continuous(labels = scales::label_comma())
print(base)
```

2024 numbers: 35,493

Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending December 28, 2024 (Week 52)

(Accessible Version: https://wonder.cdc.gov//nndss/static/2024/52/2024-52-table990.html)


	Pertussis					
Reporting Area	Current week	Previous 52 weeks Max +	Cum YTD 2024 +	Cum YTD 2023 +		
New Mexico	-	9	101	41		
Utah	1	13	263	238		
Wyoming	-	0	-	-		
Pacific	16	254	5,508	799		
Alaska	5	48	595	26		
California	4	68	1,775	643		
Hawaii	-	7	70	3		
Oregon	5	50	1,039	40		
Washington	2	139	2,029	87		
U.S. Territories	-	3	57	36		
American Samoa	-	0	-	-		
Commonwealth of Northern Mariana Islands	-	0	-	-		
Guam	-	1	5	-		
Puerto Rico	-	3	52	36		
U.S. Virgin Islands	-	0	-	-		
Non-U.S. Residents	-	1	1	-		
Total	212	1,619	35,493	7,099		


Vaccine	Trade Name	Manufacturers	Components (Concentrations)		
DTaP	Daptacel,	Sanofi Pasteur,	Inactivated PT: 10-20 μg, FHA: 5-20 μg,		
	Infanrix	GlaxoSmithKline	PRN: 3-5 μg, FIM 2+3: 5-10 μg		
Тдар	Adacel,	Sanofi Pasteur,	Inactivated PT: 2.5-8 μg, FHA: 5-8 μg,		
	Boostrix	GlaxoSmithKline	PRN: 3-5 μg, FIM 2+3: 5-8 μg		


Vaccine	Trade Name	Manufacturers	Components (Concentrations)		
DTaP	Daptacel,	Sanofi Pasteur,	Inactivated PT: 10-20 μg, FHA: 5-20 μg,		
	Infanrix	GlaxoSmithKline	PRN: 3-5 μg, FIM 2+3: 5-10 μg		
Tdap	Adacel,	Sanofi Pasteur,	Inactivated PT: 2.5-8 μg, FHA: 5-8 μg,		
	Boostrix	GlaxoSmithKline	PRN: 3-5 μg, FIM 2+3: 5-8 μg		

The two aP vaccine formulations (DTaP and Tdap) differ in their concentrations of Pertussis derived antigens.

Higher concentrations are thought to be necessary for the initial building of immunity in young children








Source: Centers for Disease Control

Vaccine development exploits <u>adaptive immunity</u>



The adaptive immune response is antigen specific & can be long lasting

- Adaptive immune defenses are:
 - Mediated primarily by T cells, B cells and antibodies.
 - Specific for particular antigens (foreign substance or molecule) and are specialized to provide the best protection.
 - Diverse in their specificity.
 - Enhance with each repeated exposure (express Immunologic memory) providing lasting protection from future challenges).
 - Capable of self/non-self recognition.

Antibodies

Y shaped proteins, made by B cells, that bind specific antigens to sequester & neutralize germs & activate other immune cells.

Major types include:

- <u>IgG</u>: The most abundant antibody in blood. With four sub-classes (IgG1 to IgG4) crucial for long-term immunity and responding to bacterial & viral infections.
- IgA: Found primarily in mucous membranes and body secretions like saliva and breast milk.
- IgM: The first antibody produced in response to an infection, important in early immune responses.
- IgE: Involved in allergic reactions and defense against parasitic infections.


•••	• < >	Home Gmail Gcal GitHub BIMM143	BGGN213 GDrive Atmosphere CloudLaunch BIMM194	Blink News • + •	û + C
70+ 31			C https://www.cmi-pb.org		
		CMPUTATIONAL MODELS OF IMMUNITY PERTUSSIS BOOST		Sign in to CMI-PI	B
	Ab titer	\$		Search	
	The missic	-	community with a comprehensive, high- Pertussis booster vaccination.	quality and freely accessible resource o	f
		LEARN ABOUT THE PROJECT	UNDERSTAND THE DATA	ACCESS THE DATA	
				(RI)	
		The NIH funded CMI network What is pertussis vaccination?	How do we measure immune responses? What data is available?	Data statistics Use the API in your programs Download all data (SFTP)	
		What are the open scientific questions? The CMI-PB approach: A community	Our approach to data standardization Browse our terminology	More	

https://www.cmi-pb.org/


	Home Gmail Gcal GitHub BIMM143	BGGN213 GDrive Atmosphere CloudLaunch BIMM194	
Ab titer	COMPUTATIONAL MODELS OF IMMUNITY — PERTUSSIS BOOST —		Search
The mis	sion of CMI-PB is to provide the scientific P	community with a comprehensive, high- Pertussis booster vaccination.	-quality and freely accessible resource of
	LEARN ABOUT THE PROJECT	UNDERSTAND THE DATA	ACCESS THE DATA
	The NIH funded CMI network What is pertussis vaccination? What are the open scientific questions? The CMI-PB approach: A community	responses? What data is available? Our approach to data standardization Browse our terminology	Use the API in your programs Download all data (SFTP) More

https://www.cmi-pb.org/

Blood samples are taken at different time-points both pre- and post booster vaccination




These samples undergo multi-omics characterization




This includes:

- PBMC cell frequencies by flow cytometry
 - Total of 37 distinct cell populations
- Plasma antigen-specific antibody titers
 - Antibody Isotypes: IgG, IgG1, IgG2, IgG3, IgG4
 - Vaccine antigens
 - Pertussis Toxin (PT), PRN, FHA, FIM2/3
 - Tetanus Toxoids (TT)
 - Diphtheria Toxoids (DT)
 - OVA (irrelevant control)
- Plasma proteomics by Olink
 - Concentration of 45 cytokines
- Transcriptomics by bulk RNA-Seq

CMI-PB provides access to experimental data in a standardized format



CMI-PB provides access to experimental data in a standardized format



Database Information Tables

SUBJECT

subject_id

infancy_vac

biological_sex

ethnicity

race

year_of_birth

date_of_boost

dataset

SPECIMEN

specimen_id

subject_id

actual_day_relative_to_boost

planned_day_relative_to_boost

specimen_type


visit

Side Note: Dates and times...



Michael Donohoe 🤣 @donohoe

Comprehensive map of all countries in the world that use the MMDDYYYY format



2:29 PM · May 11, 2015 · Twitter Web Client

PUBLIC SERVICE ANNOUNCEMENT:

OUR DIFFERENT WAYS OF WRITING DATES AS NUMBERS CAN LEAD TO ONLINE CONFUSION. THAT'S WHY IN 1988 ISO SET A GLOBAL STANDARD NUMERIC DATE FORMAT.

THIS IS THE CORRECT WAY TO WRITE NUMERIC DATES:

2013-02-27

THE FOLLOWING FORMATS ARE THEREFORE DISCOURAGED:

Image credit: XKCD https://xkcd.com/1179/

Database Information Tables

SUBJECT

subject_id

infancy_vac

biological_sex

ethnicity

race

year_of_birth

date_of_boost

dataset

SPECIMEN

specimen_id

subject_id


actual_day_relative_to_boost

planned_day_relative_to_boost

specimen_type


visit

Dplyr *_join() functions...




Information Tables

dataset



40

Information Tables



date_of_boost

dataset

We Want One Meta table

SUBJECT

subject_id

infancy_vac

biological_sex

ethnicity

race


year_of_birth

date_of_boost

dataset


specimen_id
subject_id
actual_day_relative_to_boost
planned_day_relative_to_boost
specimen_type
visit
infancy_vac
biological_sex
ethnicity
race
year_of_birth
date_of_boost
dataset

META



42

CMI-PB provides access to experimental data in a standardized format



Join with Experement Tables

USE DPLYR *_JOIN() FUNCTIONS...

...

META	PLASMA_AB_TITER
specimen_id	specimen_id
subject_id	isotype
actual_day_relative_to_boost	is_antigen_specific
planned_day_relative_to_boost	antigen
specimen_type	MFI
visit	MFI_normalised
infancy_vac	unit
biological_sex	lower_limit_of_detection
ethnicity	

ABDATA

specimen_id

subject_id

actual_day_relative_to_boost

planned_day_relative_to_boost

specimen_type

visit

infancy_vac

biological_sex

ethnicity

race

year_of_birth

date_of_boost

dataset

isotype

is_antigen_specific

antigen

MFI

MFI_normalised


unit

lower_limit_of_detection

Meta + Experiment


META	+	AB_TITER
specimen_id		specimen_id
subject_id		isotype
actual_day_relative_to_boost		is_antigen_specific
planned_day_relative_to_boost		antigen
specimen_type		MFI
visit		MFI_normalised
infancy_vac		unit
biological_sex		lower_limit_of_detection
ethnicity		

•••




CMI-PB 2021 dataset IgG PT

Dashed lines at day 0 (pre boost) and day 14 (post boost)



CMI-PB 2021 dataset IgG PT

Dashed lines at day 0 (pre boost) and day 14 (post boost)



		Cmi-pb.org	5		⊕ [^) +	Ē
	Home Gma	il Gcal GitHub BIMM143 BGGN213 GDrive Atmosphere CloudL	aunch BIMM194 Blink Ne	ews → + →			
₩ 31	C https://www.cmi-pb.org	/terminology/uniprot:Q5I8X0	똃 fim2 - Fimbrial prote	ein - Bordetella pertussis UniProtKB Un	niProt		
	CMI-F	DST —		<u>Sign in to C</u>	MI-PB		
	Terminology	FIMbrial protein		Search			
	Terminology Browser	Fimbrial protein Fimbrial protein Fim3		uniprot:Q5I8X0			
	Fimbrial prote	Mixture of Eim 2 and Eim 2					
	https://www.uniprot.org/un	prot/Q5I8X0					
	Ontology Class material entity molecular entity protein Fimbrial prote Annotation Property Data Property Object Property Individual	 label Fimbrial prote CMI-PB alternative fim2 type Class subclass of protein 					
	Detetine						

••• • • • >		uniprot.org	Ś	⊕ £ + C
	Home Gmail Gcal GitHub BIMM		CloudLaunch BIMM194 Blink News → + →	
₩ 31	C https://www.cmi-pb.org/terminology/uniprot:Q518	X0	🤫 fim2 - Fimbrial protein - Bordetella pertuss	sis UniProtKB UniProt
UniProt BLAST Align	Peptide search ID mapping SPARQL	UniProtKB 🗸	Advanced Lis	t Search 🍰 ᡠ 🎦 Help
Function	🖹 Q518X0 · Q518	3X0_BORPT		
Names & Taxonomy	Protein ⁱ Fimbrial prote	ein	Amino acids 207	
Subcellular Location	Status ⁱ 🗈 UniProtKB	unreviewed (TrEMBL)	Protein Predicted	
Phenotypes & Variants	Organism ⁱ Bordetella pe	rtussis	existence ⁱ	
PTM/Processing	Gene ⁱ fim2		Annotation 1/5 score ⁱ	
Expression				
Interaction	Entry Feature viewer Po	ublications External links	History	Feedback
Structure	BLAST Align 🛨 Download 🗸 🇰	Add Add a publication Entry fe	edback	ے ا
Family & Domains	Function			
Sequence	Function			
Similar Proteins	GO Annotations ¹			
	Slimming set:			ि मुख्य
	Science			Ľ
				<i>b</i> .
				tivity
We'd like to inform you that we ha	ve updated our Privacy Notice to comply with	Europe's new General Data Protectior	Regulation (GDPR) that applies since 25 May 2018.	Accept

$\bullet \bullet \bullet \Box \mid \checkmark < >$		uniprot.org	(2	⊕ ⊥ + □
	Home Gmail Gcal GitHub BI	/IM143 BGGN213 GDrive Atmosphere	CloudLaunch BIMM194 Blin	k News 🛩 + 🛩	
▶ 🖬 🖸 ► htt	ps://www.cmi-pb.org/terminology/uniprot:Q5	I8X0	뼳 fim2 - Fimbri	ial protein - Bordetella pertussis UniProtKB I	UniProt
UniProt BLAST Align Pepti	de search ID mapping SPARQL	UniProtKB 🗸		Advanced List Search	🖴 ᡠ 🖄 Help
Function	🖿 Q5I8X0 · Q5I	8X0_BORPT			
Names & Taxonomy	Protein ⁱ Fimbrial pro	tein	Amino acids	207	
Subcellular Location	Status ⁱ 📄 UniProtK	B unreviewed (TrEMBL)	Protein	Predicted	
Phenotypes & Variants	Organism ⁱ Bordetella p	pertussis	existence ⁱ		
PTM/Processing	Gene ⁱ fim2		Annotation score ⁱ	1/5	
Expression					
Interaction	Entry Feature viewer	Publications External links	History		Feedback
Structure	BLAST Align 土 Download 🗸	🗃 Add Add a publication Entry f	eedback		
Family & Domains	Functioni	refet	ee ^{e5}	<i>b</i> 3;	
Sequence	Function	wes and e cription	abolicaro es	e ellopat	×
Similar Proteins	GO Annotations ⁱ Slimming set:	ces chores about a stiplised tart	estimate solution	Foreigent operation protecti	es det and the state of the sta
	generic •	soon soon the soon of the soon		Notation and the such of the state of the st	
				Cone of the astrony the sport of the strain of the sport	and the of the original and the original the set of the original the o
		ie due cur aus cost un de de autre l'interation in	in the stand we we do be the the out of	1. 64. 36. 20 20 40. ev. 10. 10. 100 900 200 60 20 40 00	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
		Cell color indicative of number of GO term	ns		
We'd like to inform you that we have upd		ASPECT	TEF	RM	
		Cellular Component	pilu	IS C Source:InterPro	
		Biological Process	cell	adhesion 🖸 📃 Source:InterPro	
			2		Expand table 5

	Image: Second	ſ
	ps://www.cmi-pb.org/terminology/uniprot:Q5/8X0 () fim2 - Fimbrial protein - Bordetella pertussis UniProtKB UniProt	
UniProt BLAST Align Peptic	de search ID mapping SPARQL UniProtKB - Advanced List Search 🖨 🏠 🖄	Help
Function		
Names & Taxonomy	Subcellular Location ¹	
Subcellular Location		
Phenotypes & Variants	UniProt Annotation GO Annotation	
PTM/Processing	♥ pilus ⊑	
Expression Interaction Structure Family & Domains Sequence Similar Proteins	Complete GO annotation on QuickGO L ²	Feedback
		Help
We'd like to inform you that we have und	ated our Privacy Notice to comply with Europe's new General Data Protection Regulation (GDPR) that applies since 25 May 2018.	+

	Image:	org Č	⊕ Û + D	ל	
	Home Gmail Gcal GitHub BIMM143 BGGN213 GDrive Atr				
	os://www.cmi-pb.org/terminology/uniprot:Q5I8X0	🧑 fim2 - Fimbrial protein - Bordetella pertussis UniProtKB Un	iProt		
UniProt BLAST Align Peptic	de search ID mapping SPARQL UniProtKB -	Advanced List Search	📤 ᡠ 🖸 Help		
Function					
Names & Taxonomy	Subcellular Location				
Subcellular Location					
Phenotypes & Variants	UniProt Annotation GO Annotation				
PTM/Processing		♥ pilus 🖾			
Expression		Complete GO annotation on QuickGO L ³		¥	
Interaction				Feedback	
Structure	Fimbrium				
Family & Domains	Con a constant of the constant	A fimbrium or pilus is a hair-like, non-flagellar, polymeric filamentous appendage that extend f	from		
Sequence	the bacterial or archaeal cell surface, such as type 1 pili, P-pili, type IV pili or curli. Pili perform a variety of				
Similar Proteins					
		functions, including surface adhesion, motility,	<u>a</u>	Help	
		interactions, biofilm formation, conjugation, DN uptake, and twitching motility.			

We'd like to inform you that we have updated our Privacy Notice to comply with Europe's new General Data Protection Regulation (GDPR) that applies since 25 May 2018.

1

Accept

Prediction challenges




			Number o		
	Annual prediction challenge title	Contestants	Training dataset	Test dataset	Current status
1	First Challenge: Internal dry run	CMI-PB consortium	60 (28 aP + 32 wP)	36 (19 aP + 17 wP)	May 2022
2	Second Challenge: Invited challenge	Invited contestants	96 (47 aP + 49 wP)	22 (13 aP + 9 wP)	Announced on September 12, 2023
3	Third Challenge: Open Challenge 1	Public	118 (60 aP + 58 wP)	32 (16 aP + 16 wP)	Will be announced in April 2024
4	Fourth Challenge: Open Challenge 2	Public	150 (76 aP + 74 wP)	32 (16 aP + 16 wP)*	Will be announced in December 2024



2nd CMI-PB Prediction Challenge Outline


Revolutionizing computational modelling approaches for immune response prediction





Previously identified vaccine responses are formulated as prediction tasks

These include:

- Plasma IgG levels are increased at day 14 post-booster vaccination compared to baseline
- Increase in the percentage of monocytes on day 1 post-booster over baseline
- A subset of aP-primed individuals showed an increased expression of proinflammatory genes, including CCL3, at day 3 post-booster vaccination when compared to wP primed individuals.







Prediction tasks

1) Antibody titer tasks

1.1) Rank the individuals by IgG antibody titers against pertussis toxin (PT) that we detect in plasma 14 days post booster vaccinations.

1.2) Rank the individuals by fold change of IgG antibody titers against pertussis toxin (PT) that we detect in plasma 14 days post booster vaccinations compared to titer values at day 0.

2) Cell frequencies tasks

2.1) Rank the individuals by predicted frequency of Monocytes on day 1 post boost after vaccination.2.2) Rank the individuals by fold change of predicted frequency of Monocytes on day 1 post booster vaccination compared to cell frequency values at day 0.

3) Gene expression tasks

3.1) Rank the individuals by predicted gene expression of CCL3 on day 3 post-booster vaccination.3.2) Rank the individuals by fold change of predicted gene expression of CCL3 on day 3 post booster vaccination compared to gene expression values at day 0.


Example of Rankings

	Subject ID	Predicted value	Rank
	101	2.9	4
	102	9.1	1
r	103	1.2	5
-	104	4.5	3
	105	4.7	2



The CMI-PB team:





And thank you to the Sette Lab, Crotty lab, LJI Clinical Core, LJI Bioinformatics Core